Title: Study of Lipid profile in chronic kidney disease patients

Authors: Dr Sarita H Patel, Dr Milav Bhavsar, Dr Alok Parekh, Dr Rinku Bhanavadiya

 DOI: https://dx.doi.org/10.18535/jmscr/v7i4.113

Abstract

Background: Chronic kidney disease (CKD) is associated with premature atherosclerosis and increased incidence of cardiovascular morbidity and mortality. Several factors contribute to atherogenesis and cardiovascular disease in patients with CKD. Notable among the CKD-induced risk factors are lipid disorders, oxidative stress, inflammation, physical inactivity, anemia, hypertension, vascular calcification, endothelial dysfunction, and depressed nitric oxide availability.

Objective: To assess the pattern of lipid profile in chronic kidney disease patients along with comparision of lipid profile in chronic kidney disease patients with diabetes mellitus and without diabetes mellitus.

Methods: A total of 50 patients of chronic kidney disease (CKD)of age group 20-70 year and 50 age and sex matched healthy controls were included in this study. Blood specimens were collected from both groups and measurement of the lipid prfile, FBS, PPBS, S.creatinine and blood urea was done and compare results with the study group.

Results: Total cholesterol and LDL was significantly raised in patients of CKD compared to controls The triglycerides were elevated. However, the statistical analysis showed that it was not significant. There was statistically significant variation found in triglyceride, VLDL and HDL when compared with the comorbid conditions of hypertension.

Conclusion: There is significant amount of dyslipidemia is found in patients of CKD. so treatment of dyslipidemia will reduce mortality in CKD patients.

Keywords: CKD, lipid Profile, Hypertension, Diabetes mellitus.

References

  1. Lidner A, Charra B, Sherrard D. Accelerated atherosclerosis in prolonged Maintainance hemodialysis. N Engl J Med 1974;290:697-701.
  2. Tetsuo Shoji, Eiji Ishimura, Masaaki Inaba, Tsutomu Tabata, yoshiki Nishizawa. Atherogenic Lipoproteins in End-stage renal disease. Am J kidney dis 2001;38:S30-S33
  3. Foley RN, Parfrey PS, and Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112–S119, 1998
  4. David CW,Ravinder  Oxidation  of  LDL  by  mesangial  cells  may  promote  glomerular  injury. Kidney  Int  1994;45:  1628-36
  5. Vaziri ND,  Sato  T,  Liang K. Molecular  mechanisms  of  altered   cholesterol  metabolism  in focal glomerulosclerosis.  Kidney  Int  2003;63:1756-63.
  6. Abrass   Cellular  lipid   metabolism  and  the  role of  lipids  in  progressive  renal  disease. Am  J  Nephrol 2004; 24:46-53. 
  7. .Attman PO, Samuelsson O, and Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 21: 573–592, 1993
  8. Gerald appel, Jordan J Cohen, John T Harrington, Cheryl J Zusman. Lipid abnormalities in renal disease. Kidney int 1991;39:169-183
  9. Thomas Quaschning, Vera Krane, Thomas Metzger, Christoph Wanner. Abnormalities in uremic Lipoprotein Metabolism and it’s impact on cardiovascular disease. Am J kidney dis 2001;38:S14-S19
  10. CM Chan. Hyperlipidemia in  chronic  kidney  Ann AcadMed  Singapore  2005;35:31-35
  11. Nayak  KC, Saini  MS, Singh  VB,  Verma SK, Tanwar  RS,  Charanjeet  Carotid  artery  intima  - media  thickness  and its  relation  with  lipid  profile in non-diabetic uremic  patients.  Indian  J  Nephrol  2006;16:170-3
  12. Sharma BK, Jindal SK, Rana  DS, Gupta  B,  Kumar    Absence of hyperlipidemia in patients  of chronic  renal  failure in Chandigarh.Ind.J.Med. Res 1980; 72:461-64.

Corresponding Author

Dr Milav Bhavsar

Associate Professor, Department of Biochemistry, C.U Shah Medical College, Surendranagar, Gujarat, India, Pin: 363001

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.